Ablynx NV is exploring all options for its rheumatoid arthritis compound, ATN-103, which was returned to the company by Pfizer in late 2011 only months after it had achieved proof-of-concept in a Phase 2 clinical trial. ---Subscribe to MedNous to access this article--- Company News
